Breaking News Instant updates and real-time market news.

RP

RealPage

$62.84

1.21 (1.96%)

18:39
07/09/19
07/09
18:39
07/09/19
18:39

RealPage initiated with an Outperform at Keefe Bruyette

Keefe Bruyette analyst Ryan Tomasello started RealPage with an Outperform rating and $74 price target. The company is levered to the digitization of one of the world's largest asset classes, commercial real estate, Tomasello tells investors in a research note. He believes secular tailwinds along with the company's subscription-based model should produce "strong through-cycle performance."

  • 13

    Nov

RP RealPage
$62.84

1.21 (1.96%)

03/28/19
DADA
03/28/19
INITIATION
Target $60
DADA
Neutral
RealPage initiated with a Neutral at DA Davidson
DA Davidson analyst Peter Heckmann initiated RealPage with a Neutral rating and a price target of $60. The analyst believes that the company is "well positioned" to further generate "attractive growth in revenue and earnings" with "solid organic growth, steady margin expansion, and additional accretive acquisitions". Heckmann adds however that its current valuation is toward the high end of its historical range. The analyst expects to become more constructive on RealPage in the event of its stock price pullback.
02/26/19
BNCH
02/26/19
NO CHANGE
Target $64
BNCH
Buy
RealPage implementation problems 'easily fixable,' says Benchmark
Benchmark analyst Mark Schappel keeps a Buy rating on RealPage following the company's Q4 report, stating that while the revenue shortfall was disappointing, profitability measures, including cash flow from operations, were strong. He said management outlined a strategy to address its product implementation issues and Schappel thinks most of the company's implementation issues are fixable in a reasonable time. He has a $64 price target on RealPage shares.
02/26/19
SPHN
02/26/19
NO CHANGE
Target $70
SPHN
Overweight
Stephens does not see cause for concern in RealPage's 'fairly soft' guidance
Stephens analyst John Campbell said RealPage delivered "a mixed quarter and fairly soft guidance," but he does not see a cause for concern, arguing that the company's drawn out implementation timelines are "a rich man's problem" in that they are partly driven by the degree of bookings success RealPage is having in one of its most promising long-term offerings, namely Asset Optimization. He maintains an Overweight rating and $70 price target on RealPage shares following the company's quarterly report.
02/26/19
JPMS
02/26/19
NO CHANGE
Target $70
JPMS
Overweight
RealPage share setup better for remainder of 2019, says JPMorgan
JPMorgan analyst Sterling Auty lowered his price target for RealPage to $70 while keeping an Overweight rating on the shares. Revenue in Q4 was shy of expectations, and for the second quarter in a row the revenue guidance was disappointing, Auty tells investors in a post-earnings research note. However, the issue does not appear related to demand but rather related to customer implementations being less efficient as customers are buying more products in each of these larger deals, says the analyst. In addition, Auty attributes some of the guidance to the new CFO Tom Ernst taking a prudent approach. He believes the setup for RealPage shares should better for the remainder of 2019.

TODAY'S FREE FLY STORIES

W

Wayfair

$144.97

-0.28 (-0.19%)

, BBBY

Bed Bath & Beyond

$9.35

-0.56 (-5.65%)

07:46
07/23/19
07/23
07:46
07/23/19
07:46
Recommendations
Wayfair, Bed Bath & Beyond, Macy's analyst commentary  »

Wayfair well positioned…

W

Wayfair

$144.97

-0.28 (-0.19%)

BBBY

Bed Bath & Beyond

$9.35

-0.56 (-5.65%)

M

Macy's

$22.10

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 01

    Aug

  • 05

    Aug

IDRA

Idera Pharmaceuticals

$2.54

0.02 (0.79%)

07:46
07/23/19
07/23
07:46
07/23/19
07:46
Hot Stocks
Idera Pharmaceuticals appoints Elizabeth Tarka as CMO, John Kirby as CFO »

Idera Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APD

Air Products

$225.97

1.455 (0.65%)

07:46
07/23/19
07/23
07:46
07/23/19
07:46
Recommendations
Air Products analyst commentary  »

Air Products price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 06

    Aug

  • 22

    Aug

MRNS

Marinus Pharmaceuticals

$3.99

0.11 (2.84%)

07:45
07/23/19
07/23
07:45
07/23/19
07:45
Hot Stocks
Marinus Pharmaceuticals announces data from Phase 2 Amaryllis study »

The Amaryllis Study…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRNS

Marinus Pharmaceuticals

$3.99

0.11 (2.84%)

07:44
07/23/19
07/23
07:44
07/23/19
07:44
Hot Stocks
Marinus Pharmaceuticals announces data from Phase 2 Magnolia clinical trial »

Marinus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDNS

Cadence Design

$72.68

-0.21 (-0.29%)

07:43
07/23/19
07/23
07:43
07/23/19
07:43
Recommendations
Cadence Design analyst commentary  »

Cadence Design price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITRI

Itron

$60.62

0.77 (1.29%)

07:43
07/23/19
07/23
07:43
07/23/19
07:43
Recommendations
Itron analyst commentary  »

Canaccord sees several…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Aug

RDHL

RedHill Biopharma

$8.35

0.24 (2.96%)

07:41
07/23/19
07/23
07:41
07/23/19
07:41
Hot Stocks
RedHill Biopharma continues to enroll patients in Phase 2a study of YELIVA »

The ongoing Phase 2a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

FBP

First BanCorp

$10.74

-0.25 (-2.27%)

07:40
07/23/19
07/23
07:40
07/23/19
07:40
Earnings
First BanCorp reports Q2 EPS 19c, consensus 19c »

Reports Q2 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

RDHL

RedHill Biopharma

$8.35

0.24 (2.96%)

07:40
07/23/19
07/23
07:40
07/23/19
07:40
Hot Stocks
RedHill Biopharma 'working toward' confirmatory Phase 3 study for BEKINDA »

RedHill is currently…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

07:40
07/23/19
07/23
07:40
07/23/19
07:40
General news
Treasury Market Outlook: Treasury yields are modestly cheaper »

Treasury Market Outlook:…

ATI

Allegheny Technologies

$25.11

-0.175 (-0.69%)

07:39
07/23/19
07/23
07:39
07/23/19
07:39
Earnings
Allegheny Technologies reports Q2 ex-items EPS 40c, consensus 34c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 06

    Aug

RDHL

RedHill Biopharma

$8.35

0.24 (2.96%)

07:39
07/23/19
07/23
07:39
07/23/19
07:39
Hot Stocks
RedHill Biopharma to initiate Phase 3 study activities with RHB-204 in Q4 »

RedHill plans to initiate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

NOW

ServiceNow

$293.30

3.48 (1.20%)

07:39
07/23/19
07/23
07:39
07/23/19
07:39
Recommendations
ServiceNow analyst commentary at Needham »

ServiceNow price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

RDHL

RedHill Biopharma

$8.35

0.24 (2.96%)

07:39
07/23/19
07/23
07:39
07/23/19
07:39
Hot Stocks
RedHill Biopharma says FDA meetings for RHB-104 to take place in 2H198 »

FDA meetings are planned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

RDHL

RedHill Biopharma

$8.35

0.24 (2.96%)

07:38
07/23/19
07/23
07:38
07/23/19
07:38
Hot Stocks
RedHill Biopharma plans U.S. launch of Talicia in 4Q19 »

The U.S. Food and Drug…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

CR

Crane

$86.50

0.99 (1.16%)

, CIR

Circor

$39.83

1.17 (3.03%)

07:37
07/23/19
07/23
07:37
07/23/19
07:37
Recommendations
Crane, Circor analyst commentary  »

Crane Q2 highlighted by…

CR

Crane

$86.50

0.99 (1.16%)

CIR

Circor

$39.83

1.17 (3.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 01

    Aug

  • 09

    Sep

  • 09

    Sep

RLGY

Realogy

$5.17

-0.08 (-1.52%)

, AMZN

Amazon.com

$1,985.93

21.15 (1.08%)

07:37
07/23/19
07/23
07:37
07/23/19
07:37
Hot Stocks
Realogy launches TurnKey in collaboration with Amazon »

Realogy (RLGY) announced…

RLGY

Realogy

$5.17

-0.08 (-1.52%)

AMZN

Amazon.com

$1,985.93

21.15 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 08

    Aug

AN

AutoNation

$42.01

-0.045 (-0.11%)

07:36
07/23/19
07/23
07:36
07/23/19
07:36
Recommendations
AutoNation analyst commentary  »

Stephens 'not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 13

    Nov

MYOV

Myovant Sciences

$8.15

-0.25 (-2.98%)

07:36
07/23/19
07/23
07:36
07/23/19
07:36
Hot Stocks
Myovant Sciences says primary efficacy endpoint met in LIBERTY 2 study »

Myovant Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMB

Kimberly-Clark

$134.40

-1.31 (-0.97%)

07:36
07/23/19
07/23
07:36
07/23/19
07:36
Earnings
Kimberly-Clark sees FY19 net sales flat to down 1% y/y, consensus $18.41B »

Prior assumption was down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

FB

Facebook

$202.32

3.94 (1.99%)

07:35
07/23/19
07/23
07:35
07/23/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

ARAY

Accuray

$3.91

-0.07 (-1.76%)

07:34
07/23/19
07/23
07:34
07/23/19
07:34
Hot Stocks
CNNC Accuray Medical Technology receives safety license in China »

Accuray provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

CYTK

Cytokinetics

$11.65

0.49 (4.39%)

, ALPMY

Astellas Pharma

$0.00

(0.00%)

07:34
07/23/19
07/23
07:34
07/23/19
07:34
Hot Stocks
Cytokinetics granted European orphan designation for reldesemtiv »

Cytokinetics Incorporated…

CYTK

Cytokinetics

$11.65

0.49 (4.39%)

ALPMY

Astellas Pharma

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

KMB

Kimberly-Clark

$134.40

-1.31 (-0.97%)

07:32
07/23/19
07/23
07:32
07/23/19
07:32
Hot Stocks
Kimberly-Clark CEO says 'we made excellent progress in the second quarter' »

CEO Mike Hsu said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.